U.S. Food and Drug Administration, Center for Drug Evaluation and Research

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Explore the latest insights on cancer treatments, product approvals, and safety updates through this informative podcast series focused on oncology and drug development.

Listen on Apple Podcasts

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

3 mins • Jan 17, 2025

Recent Episodes

Jan 17, 2025

FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

3 mins

Dec 30, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

3 mins

Nov 18, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma

3 mins

Nov 14, 2024

FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma

4 mins

Aug 16, 2024

FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer

5 mins

Language
English
Country
United States
Website
Request an Update
Updates may take a few minutes.